POM-V Prescription Required Companion Animal

Metrotab Vet. Flavoured 500 mg Tablets for Dogs and Cats

Active ingredient: Metronidazole

Form

Tablet

Species

Cats Dogs

Manufacturer

CP Pharma Handelsgesellschaft mbH

VMD MA No.

20916/4040

What it's used for

Treatment of gastrointestinal tract infections caused by Giardia spp. and Clostridia spp. (i.e. C. perfringens ). Treatment of infections of the urogenital...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Metronidazole

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Metrotab Vet. Flavoured 500 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Treatment of gastrointestinal tract infections caused by Giardia spp. and Clostridia
spp. (i.e. C. perfringens ).
Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by
obligate anaerobic bacteria (e.g. Clostridia spp.) susceptible to metronidazole.

Oral use
The recommended dose is 50 mg metronidazole per kg bodyweight (one 500 mg
tablet/10 kg bodyweight) per day, for 5 - 7 days. The daily dose should preferably be
divided in two equal doses for twice daily administration (i.e. 25 mg/kg bodyweight
twice daily).
To ensure administration of the correct dosage, bodyweight should be determined as
accurately as possible.
Number of tabletsTwice daily
Bodyweight
(kg)
MorningEvening
Once daily
2.5 kg¼5 kg¼¼½10 kg½½115 kg¾¾1 ½20 kg11225 kg1 ¼1 ¼2 ½30 kg1 ½1 ½335 kg1 ¾1 ¾3 ½40 kg224

Revised: October 2023
AN: 01657/2023 & 01658/2023Page 4 of 6
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the
tablet on a flat surface, with its scored side facing up and the convex (rounded) side
facing the surface.
Halves: press down with your thumbs or fingers on both sides of the tablet.
Quarters: press down with your thumb or a finger in the middle of the tablet.
Divided tablets should be used at the next administration. Any divided tablets
remaining after the last administration of the product should be discarded.

Do not use in cases of hepatic disorders.
Do not use in known cases of hypersensitivity to the active substance or to any of the
excipients.

The following adverse reactions may occur after administration of metronidazole:
vomiting, hepatotoxicity and neutropenia. In very rare cases neurological signs may
occur. In the dog, (cerebellovestibular) ataxia and (vertical) nystagmus were amongst
the most frequently reported neurological signs.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Revised: October 2023
AN: 01657/2023 & 01658/2023Page 3 of 6

None.

Revised: October 2023
AN: 01657/2023 & 01658/2023Page 2 of 6

Special precautions for use in animals
Due to the likely variability (time, geographical) in the occurrence of metronidazole
resistant bacteria, bacteriological sampling and susceptibility testing are
recommended.
Whenever possible, the product should only be used based on susceptibility testing.
Official, national and regional antimicrobial policies should be taken into account
when the veterinary medicinal product is used.
Especially after prolonged treatment with metronidazole neurological signs could
occur.
As tablets are flavoured, store tablets out of reach of the animals in order to avoid
accidental ingestion.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Metronidazole has confirmed mutagenic and genotoxic properties in laboratory
animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory
animals and has possible carcinogenic effects in humans. However, there is
inadequate evidence in humans for the carcinogenicity of metronidazole.
Metronidazole may be harmful for the unborn child.
Pregnant women should be careful when handling this veterinary medicinal product.
Impervious gloves should be worn during administration of the product to avoid skin
and hand-to-mouth contact with the product.
To avoid accidental ingestion, particularly by a child, unused part-tablets should be
returned to the open blister space, inserted back into the outer packaging and kept in
a safe place out of the sight and reach of children. In case of accidental ingestion,
seek medical advice immediately and show the package leaflet or the label to the
physician.
Metronidazole may cause hypersensitivity reactions. In case of known
hypersensitivity to metronidazole, avoid contact with the veterinary medicinal product.
Wash hands thoroughly after handling the tablets.

Metronidazole may have an inhibitory effect on the degradation of other drugs in the
liver, such as phenytoin, cyclosporine and warfarin.
Cimetidine may decrease the hepatic metabolism of metronidazole resulting in
increased serum concentration of metronidazole.
Phenobarbital may increase hepatic metabolism of metronidazole resulting in
decreased serum concentration of metronidazole.

This veterinary medicinal product does not require any special storage conditions.
Return any divided tablet to the blister.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.